Please wait a minute...
文章检索
预防医学  2025, Vol. 37 Issue (1): 40-45    DOI: 10.19485/j.cnki.issn2096-5087.2025.01.009
  疾病控制 本期目录 | 过刊浏览 | 高级检索 |
生物活性肽联合益生菌干预对高尿酸血症患者血尿酸水平的影响
韩丹1, 赵娅2, 黄恩善1, 叶树花3, 汪万进4, 吴方敏5, 王定良6, 章荣华1
1.浙江省疾病预防控制中心,浙江 杭州 310051;
2.杭州医学院,浙江 杭州 310059;
3.兰溪市中医院,浙江 兰溪 321100;
4.淳安县千岛湖镇社区卫生服务中心,浙江 淳安 311700;
5.长兴县煤山镇卫生院,浙江 长兴 313100;
6.桐乡市第二人民医院,浙江 桐乡 314511
Effects of bioactive peptides combined with probiotics on serum uric acid in patients with hyperuricemia
HAN Dan1, ZHAO Ya2, HUANG Enshan1, YE Shuhua3, WANG Wanjin4, WU Fangmin5, WANG Dingliang6, ZHANG Ronghua1
1. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang 310051, China;
2. Hangzhou Medical College, Hangzhou, Zhejiang 310059, China;
3. Lanxi Hospital of Traditional Chinese Medicine, Lanxi, Zhejiang 321100, China;
4. Qiandao Lake Community Health Service Center of Chun'an County, Chun'an, Zhejiang 311700, China;
5. Meishan Health Hospital of Changxing County, Changxing, Zhejiang 313100, China;
6. Tongxiang Second People's Hospital, Tongxiang, Zhejiang 314511, China
全文: PDF(887 KB)  
输出: BibTeX | EndNote (RIS)      
摘要 目的 评价生物活性肽联合益生菌干预对高尿酸血症(HUA)患者血尿酸(SUA)水平的影响,为HUA防治提供参考。方法 选择18~65岁HUA患者为研究对象,随机纳入干预组和对照组。干预组服用生物活性肽联合益生菌固体饮料3 g/d,对照组服用等量安慰剂,连续28 d;干预前通过问卷调查、体格检查和实验室检测收集基本信息、体质指数(BMI)、血压和血脂等资料;分别在干预前、干预14 d和28 d后检测SUA水平。采用广义估计方程比较两组患者干预前后SUA水平。结果 纳入HUA患者108例,其中干预组54例,对照组53例(脱落1例)。干预前,两组患者的性别、年龄、HUA病程、运动时长、饮酒频次、食用肉汤频次、BMI、高血压和血脂异常比较,差异无统计学意义(均P>0.05)。干预14 d后,干预组患者SUA水平较干预前下降3.00 μmol/L,对照组患者上升7.00 μmol/L;干预28 d后,干预组和对照组患者SUA水平较干预前分别下降26.00 μmol/L和16.00 μmol/L;干预后,两组患者SUA水平的时间与组间交互效应无统计学意义(均P>0.05)。亚组分析结果显示,干预28 d后,干预组中≥55岁和无高血压患者的SUA水平下降幅度大于对照组(均P<0.05)。结论 生物活性肽联合益生菌对HUA患者的降SUA效果与对照组无明显差异;对≥55岁和无高血压的患者干预效果较为明显。
服务
把本文推荐给朋友
加入引用管理器
E-mail Alert
RSS
作者相关文章
韩丹
赵娅
黄恩善
叶树花
汪万进
吴方敏
王定良
章荣华
关键词 生物活性肽益生菌高尿酸血症血尿酸    
AbstractObjective To evaluate the effect of bioactive peptides combined with probiotics on serum uric acid (SUA) in patients with hyperuricemia (HUA), so as to provide the evidence for prevention and treatment of HUA. Methods The patients with HUA aged 18 to 65 years were selected and randomly divided into an intervention group and a control group. The patients in the intervention group received bioactive peptides combined with probiotics for 28 days at a dose of 3 g/d, while the patients in the control group received an equal dose of placebos. Demographic information, body mass index (BMI), blood pressure and blood lipid were collected through questionnaire surveys, physical examination and laboratory tests. SUA levels were detected before and after 14 days and 28 days of interventions. The differences of SUA levels between the two groups were compared using generalized estimation equation. Results Totally 108 patients with HUA were recruited, including 54 patients in the intervention group and 53 patients in the control group (1 dropout). Before interventions, there were no statistically significant differences in gender, age, course of HUA, exercise duration, frequency of alcohol consumption, frequency of meat broth consumption, BMI, prevalence of hypertension and prevalence of dyslipidemia between the two groups (all P>0.05). After 14 days of interventions, the SUA levels of the patients in the intervention group decreased by 3.00 μmol/L, while those in the control group increased by 7.00 μmol/L. After 28 days of interventions, the SUA levels of the patients in the intervention group and the control group decreased by 26.00 μmol/L and 16.00 μmol/L, respectively. However, there was no statistically significant interaction between the intervention time and group (both P>0.05). Subgroup analysis showed that after 28 days of interventions, the decrease in SUA levels in the patients aged 55 years and older and without hypertension in the intervention group was greater than those in the control group (both P<0.05). Conclusions Bioactive peptides combined with probiotics showed no significant difference in reducing SUA levels in patients with HUA compared to the control group. The effect was more significant for patients aged 55 years and older and without hypertension.
Key wordsbioactive peptides    probiotics    hyperuricemia    serum uric acid
收稿日期: 2024-07-16      修回日期: 2024-11-05      出版日期: 2025-01-10
中图分类号:  R589.7  
基金资助:国家重点研发计划膳食营养评估和干预技术研究项目(2020YFC2006300); 中国主要营养问题的干预策略研究项目(2020YFC2006305)
作者简介: 韩丹,硕士,主管医师,主要从事营养健康工作
通信作者: 章荣华,E-mail:rhzhang@cdc.zj.cn   
引用本文:   
韩丹, 赵娅, 黄恩善, 叶树花, 汪万进, 吴方敏, 王定良, 章荣华. 生物活性肽联合益生菌干预对高尿酸血症患者血尿酸水平的影响[J]. 预防医学, 2025, 37(1): 40-45.
HAN Dan, ZHAO Ya, HUANG Enshan, YE Shuhua, WANG Wanjin, WU Fangmin, WANG Dingliang, ZHANG Ronghua. Effects of bioactive peptides combined with probiotics on serum uric acid in patients with hyperuricemia. Preventive Medicine, 2025, 37(1): 40-45.
链接本文:  
http://www.zjyfyxzz.com/CN/10.19485/j.cnki.issn2096-5087.2025.01.009      或      http://www.zjyfyxzz.com/CN/Y2025/V37/I1/40
[1] ZHANG M,ZHU X X,WU J,et al.Prevalence of hyperuricemia among Chinese adults:findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19[J/OL].Front Immunol,2021,12[2024-11-05].https://doi.org/10.3389/fimmu.2021.791983.
[2] 唐子猗,青玉凤.降尿酸药物治疗高尿酸血症及痛风的现状及研究进展[J].中华风湿病学杂志,2019,23(3):199-204.
TANG Z Y,QING Y F.Current status and research progress of urate-lowering medications for the treatment of hyperuricemia and gout[J].Chin J Rheumatol,2019,23(3):199-204.(in Chinese)
[3] YAMANAKA H,TANIGUCHI A,TSUBOI H,et al.Hypouricaemic effects of yoghurt containing Lactobacillus gasseri PA-3 in patients with hyperuricaemia and/or gout:arandomised,double-blind,placebo-controlled study[J].Mod Rheumatol,2019,29(1):146-150.
[4] 陆静,陈建,余万霰,等.复合低聚肽粉辅助营养对中国北极科考队员血尿酸的影响[J].中华损伤与修复杂志(电子版),2022,17(2):145-146.
LU J,CHEN J,YU W X,et al.The impact of compound oligopeptide powder on blood uric acid levels in Chinese Arctic expedition team members[J].Chin J Injury Repair and Wound Healing(Electron Ed),2022,17(2):145-146.(in Chinese)
[5] 中华医学会内分泌学分会.中国高尿酸血症与痛风诊疗指南(2019)[J].中华内分泌代谢杂志,2020,36(1):1-13.
Chinese Society of Endocrinology,Chinese Medical Association.Guideline for the diagnosis and management of hyperurieemia and gout in China(2019)[J].Chin J Endocrinol Metab,2020,36(1):1-13.(in Chinese)
[6] 王海莉,郭焱.酒精依赖与慢性痛发生相关性的研究进展[J].神经解剖学杂志,2023,39(1):115-118.
WANG H L,GUO Y.Research progress on the correlation between alcohol dependence and the occurrence of chronic pain[J].Chin J Neuroanat,2023,39(1):115-118.(in Chinese)
[7] 中国高血压防治指南修订委员会,高血压联盟(中国),中华医学会心血管病学分会,等.中国高血压防治指南(2018年修订版)[J].中国心血管杂志,2019,24(1):24-56.
[1] 邹艳, 黄恩善, 赵栋, 黄李春, 苏丹婷, 章荣华. 益生菌改善高尿酸血症的作用研究进展[J]. 预防医学, 2025, 37(1): 36-39.
[2] 张思雨, 夏木斯叶·木依都力, 张俊, 阿迪拉·苏力旦, 王雯雷, 依力夏提·库来西, 夏依达·乌斯满江, 张仕杰, 张荣. 新疆维吾尔自治区成人高尿酸血症的影响因素分析[J]. 预防医学, 2024, 36(6): 540-542,547.
[3] 韩明明, 吴昕钰, 杨淑娟, 肖雄, 魏咏兰, 陈恒. 成都市居民饮酒与高尿酸血症的关联研究[J]. 预防医学, 2023, 35(12): 1013-1017, 1023.
[4] 陶寄, 盛敏阳, 许云峰, 孙品晶, 钟节鸣, 王小花. 海宁市居民血脂异常的影响因素分析[J]. 预防医学, 2022, 34(8): 821-825.
[5] 玛依娜·卡哈尔, 陈邬锦, 张蓓, 梁美婷, 贺怡, 李瑞, 孙玉萍. 巴里坤县体检人群血清尿酸检测结果分析[J]. 预防医学, 2022, 34(3): 244-247.
[6] 方媛, 哈小琴. 肠道微生物与糖尿病病理机制研究进展[J]. 预防医学, 2022, 34(3): 253-257.
[7] 于莎莉, 林晨, 蒋志韬, 朱超, 赵新元. 碱性饮用水预防小鼠高尿酸血症的作用研究[J]. 预防医学, 2021, 33(8): 772-775,779.
[8] 谢飞, 胡培英, 费敏, 季淑静, 毛润越, 王颖. 血红蛋白与血尿酸的相关性研究[J]. 预防医学, 2021, 33(4): 358-363.
[9] 于宏杰, 钟培松, 袁红, 邵月琴, 彭谦, 赵琦, 赵根明. 肥胖指标预测高尿酸血症风险研究[J]. 预防医学, 2020, 32(8): 846-850.
[10] 康俏玲, 方卫莲. 2型糖尿病合并高尿酸血症患者血黏度及下肢血管流量研究[J]. 预防医学, 2020, 32(2): 175-177.
[11] 张燕, 刘亚洁, 杨雷, 加依娜·拉兹别克, 李德洋, 曹明芹. 乌鲁木齐市成年人血脂异常与高尿酸血症的关联研究[J]. 预防医学, 2020, 32(12): 1260-1264.
[12] 吴霞, 陆建林, 翁根龙. 老年代谢综合征患者尿酸、B型脑钠肽和超敏C反应蛋白水平分析[J]. 预防医学, 2019, 31(1): 59-61.
[13] 王丽君, 甘培元, 何丽雅, 陆怡, 何文芳, 徐泽汝, 郭君平, 华燕吟. 妊娠中期糖脂代谢水平与妊娠结局的相关性分析[J]. 预防医学, 2018, 30(8): 762-765,770.
[14] 李少峰, 陈燕, 董陆玲, 甄刚, 李芙琴. 张家口市体检人群高尿酸血症患病现况及影响因素分析[J]. 预防医学, 2018, 30(3): 236-239.
[15] 苏依所,倪建晓,吴文秀,郑剑勇,黄秀敏,郑建浜. 瓯海区居民血尿酸水平与代谢综合征相关性分析[J]. 预防医学, 2016, 28(7): 702-705.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed